Fortifying the Treatment of Prostate Cancer with Physical Activity

Prostate Cancer

Volumn 2016, Issue , 2016, Pages

  Champ, Colin E ^a   Francis, Lanie ^a   Klement, Rainer J ^b   Dickerman, Roger ^c   Smith, Ryan P ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b Leopoldina Hospital   (Germany)

^c Relentless Fitness   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; SEX HORMONE;

ADIPOSE TISSUE; ANDROGEN DEPRIVATION THERAPY; EXERCISE; HORMONE RELEASE; HUMAN; INFLAMMATION; LIFESTYLE MODIFICATION; MALE; METABOLIC DISORDER; MITOCHONDRIAL BIOGENESIS; MUSCLE MASS; OBESITY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION INJURY; REVIEW; TREATMENT OUTCOME;

EID: 84988561477     PISSN: 20903111     EISSN: 2090312X     Source Type: Journal    
DOI: 10.1155/2016/9462975     Document Type: Review

References (96)

1. M. V. Pilepich, K. Winter, C. A. Lawton et al., "Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31," International Journal of Radiation Oncology Biology Physics, vol. 61, no. 5, pp. 1285-1290, 2005.
2. M. Bolla, D. Gonzalez, P. Warde et al., "Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin," The New England Journal of Medicine, vol. 337, no. 5, pp. 295-300, 1997.
3. M. Roach III, J. Lu, M. V. Pilepich et al., "Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials," International Journal of Radiation Oncology Biology Physics, vol. 47, no. 3, pp. 617-627, 2000.
4. A. V. D'Amico, M.-H. Chen, A. A. Renshaw, M. Loffredo, and P. W. Kantoff, "Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial," The Journal of the American Medical Association, vol. 299, no. 3, pp. 289-295, 2008.
5. W. P. Harris, E. A. Mostaghel, P. S. Nelson, and B. Montgomery, "Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion," Nature Clinical Practice Urology, vol. 6, no. 2, pp. 76-85, 2009.
6. J. A. Efstathiou, K. Bae, W. U. Shipley et al., "Obesity and mortality in men with locally advanced prostate cancer: analysis of RTOG 85-31," Cancer, vol. 110, no. 12, pp. 2691-2699, 2007.
7. C. Rodriguez, A. V. Patel, E. E. Calle, E. J. Jacobs, A. Chao, and M. J. Thun, "Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States," Cancer Epidemiology Biomarkers and Prevention, vol. 10, no. 4, pp. 345-353, 2001.
8. Z. Gong, I. Agalliu, D. W. Lin, J. L. Stanford, and A. R. Kristal, "Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle-aged men," Cancer, vol. 109, no. 6, pp. 1192-1202, 2007.
9. Y. Cao and J. Ma, "Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis," Cancer Prevention Research, vol. 4, no. 4, pp. 486-501, 2011.
10. J. B. Meigs, P. W. F. Wilson, C. S. Fox et al., "Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease," Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 8, pp. 2906-2912, 2006.
11. R. H. Eckel, S. M. Grundy, and P. Z. Zimmet, "The metabolic syndrome," The Lancet, vol. 365, no. 9468, pp. 1415-1428, 2005.
12. R. J. Klement and C. E. Champ, "Calories, carbohydrates, and cancer therapy with radiation: exploiting the five R's through dietary manipulation," Cancer and Metastasis Reviews, vol. 33, no. 1, pp. 217-229, 2014.
13. S. J. Freedland and W. J. Aronson, "Examining the relationship between obesity and prostate cancer," Reviews in Urology, vol. 6, no. 2, pp. 73-81, 2004.
14. C. L. Amling, R. H. Riffenburgh, L. Sun et al., "Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy," Journal of Clinical Oncology, vol. 22, no. 3, pp. 439-445, 2004.
15. S. J. Freedland, W. J. Aronson, C. J. Kane et al., "Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the shared equal access regional cancer hospital database study group," Journal of Clinical Oncology, vol. 22, no. 3, pp. 446-453, 2004.
16. A. R. Shuldiner, R. Yang, and D.-W. Gong, "Resistin, obesity, and insulin resistance - the emerging role of the adipocyte as an endocrine organ," The New England Journal of Medicine, vol. 345, no. 18, pp. 1345-1346, 2001.
17. C. E. Champ, J. S. Volek, J. Siglin, L. Jin, and N. L. Simone, "Weight gain, metabolic syndrome, and breast cancer recurrence: are dietary recommendations supported by the data?" International Journal of Breast Cancer, vol. 2012, Article ID 506868, 9 pages, 2012.
18. I. Janssen, P. T. Katzmarzyk, and R. Ross, "Waist circumference and not body mass index explains obesity-related health risk," The American Journal of Clinical Nutrition, vol. 79, no. 3, pp. 379-384, 2004.
19. V. Mohamed-Ali, S. Goodrick, A. Rawesh et al., "Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-α, in vivo," Journal of Clinical Endocrinology and Metabolism, vol. 82, no. 12, pp. 4196-4200, 1997.
20. M. A. Rivas, R. P. Carnevale, C. J. Proietti et al., "TNFα acting on TNFR1 promotes breast cancer growth via p42/P44 MAPK, JNK, Akt and NF-κB-dependent pathways," Experimental Cell Research, vol. 314, no. 3, pp. 509-529, 2008.
21. V. Michalaki, K. Syrigos, P. Charles, and J. Waxman, "Serum levels of IL-6 and TNF-α correlate with clinicopathological features and patient survival in patients with prostate cancer," British Journal of Cancer, vol. 90, no. 12, pp. 2312-2316, 2004.
22. H. S. Park, J. Y. Park, and R. Yu, "Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-α and IL-6," Diabetes Research and Clinical Practice, vol. 69, no. 1, pp. 29-35, 2005.
23. P. A. McArdle, K. Mir, A. S. K. Almushatat, A. M. Wallace, M. A. Underwood, and D. C. McMillan, "Systemic inflammatory response, prostate-specific antigen and survival in patients with metastatic prostate cancer," Urologia Internationalis, vol. 77, no. 2, pp. 127-129, 2006.
24. J. L. Ryan, J. K. Carroll, E. P. Ryan, K. M. Mustian, K. Fiscella, and G. R. Morrow, "Mechanisms of cancer-related fatigue," Oncologist, vol. 12, supplement 1, pp. 22-34, 2007.
25. D. B. Greenberg, J. L. Gray, C. M. Mannix, S. Eisenthal, and M. Carey, "Treatment-related fatigue and serum interleukin-1 levels in patients during external beam irradiation for prostate cancer," Journal of Pain and Symptom Management, vol. 8, no. 4, pp. 196-200, 1993.
26. K. H. Schmitz, M. L. Neuhouser, T. Agurs-Collins et al., "Impact of obesity on cancer survivorship and the potential relevance of race and ethnicity," Journal of the National Cancer Institute, vol. 105, no. 18, pp. 1344-1354, 2013.
27. C. M. Steppan, S. T. Bailey, S. Bhat et al., "The hormone resistin links obesity to diabetes," Nature, vol. 409, no. 6818, pp. 307-312, 2001.
28. G. Boden, "Role of fatty acids in the pathogenesis of insulin resistance and NIDDM," Diabetes, vol. 46, no. 1, pp. 3-10, 1997.
29. V. Venkateswaran, A. Q. Haddad, N. E. Fleshner et al., "Association of diet-induced hyperinsulinemia with accelerated growth of prostate cancer (LNCaP) xenografts," Journal of the National Cancer Institute, vol. 99, no. 23, pp. 1793-1800, 2007.
30. R. Root-Bernstein and J. Vonck, "Glucose binds to the insulin receptor affecting the mutual affinity of insulin and its receptor," Cellular and Molecular Life Sciences, vol. 66, no. 16, pp. 2721-2732, 2009.
31. J. Beauregard, A.-C. Blouin, V. Fradet et al., "FDG-PET/CT for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy," Cancer Imaging, vol. 15, article 2, 2015.
32. S. Djiogue, A. H. N. Kamdje, L. Vecchio et al., "Insulin resistance and cancer: the role of insulin and IGFs," Endocrine Related Cancer, vol. 20, no. 1, pp. R1-R17, 2013.
33. C. E. Champ, R. Baserga, M. V. Mishra et al., "Nutrient restriction and radiation therapy for cancer treatment: when less is more," Oncologist, vol. 18, no. 1, pp. 97-103, 2013.
34. M. Iwamura, P. M. Sluss, J. B. Casamento, and A. T. K. Cockett, "Insulin-Like growth factor I: action and receptor characterization in human prostate cancer cell lines," Prostate, vol. 22, no. 3, pp. 243-252, 1993.
35. J.-P. Thissen, J.-M. Ketelslegers, and L. E. Underwood, "Nutritional regulation of the insulin-like growth factors," Endocrine Reviews, vol. 15, no. 1, pp. 80-101, 1994.
36. Y. Du, Q. Long, Y. Shi et al., "Insulin-like growth factor binding protein-3 mediates interleukin-24-induced apoptosis through inhibition of the mTOR pathway in prostate cancer," Oncology Reports, pp. 2273-2281, 2015.
37. H. Rundqvist, M. Augsten, A. Strömberg et al., "Effect of acute exercise on prostate cancer cell growth," PLoS ONE, vol. 8, no. 7, Article ID e67579, 2013.
38. S. Y. Nam, E. J. Lee, K. R. Kim et al., "Effect of obesity on total and free insulin-like growth factor (IGF)-1, and their relationship to IGF-binding protein (BP)-1, IGFBP-2, IGFBP-3, insulin, and growth hormone," International Journal of Obesity, vol. 21, no. 5, pp. 355-359, 1997.
39. R. Kaaks and P. Stattin, "Obesity, endogenous hormone metabolism, and prostate cancer risk: a conundrum of 'highs' and 'lows'," Cancer Prevention Research, vol. 3, no. 3, pp. 259-262, 2010.
40. S. A. Kenfield, M. J. Stampfer, E. Giovannucci, and J. M. Chan, "Physical activity and survival after prostate cancer diagnosis in the health professionals follow-up study," Journal of Clinical Oncology, vol. 29, no. 6, pp. 726-732, 2011.
41. E. L. Richman, S. A. Kenfield, M. J. Stampfer, A. Paciorek, P. R. Carroll, and J. M. Chan, "Physical activity after diagnosis and risk of prostate cancer progression: data from the cancer of the prostate strategic urologic research endeavor," Cancer Research, vol. 71, no. 11, pp. 3889-3895, 2011.
42. S. E. Bonn, A. Sjölander, Y. T. Lagerros et al., "Physical activity and survival among men diagnosed with prostate cancer," Cancer Epidemiology Biomarkers and Prevention, vol. 24, no. 1, pp. 57-64, 2015.
43. W. C. Miller, D. M. Koceja, and E. J. Hamilton, "A meta-analysis of the past 25 years of weight loss research using diet, exercise or diet plus exercise intervention," International Journal of Obesity, vol. 21, no. 10, pp. 941-947, 1997.
44. C. C. Curioni and P. M. Lourenço, "Long-term weight loss after diet and exercise: a systematic review," International Journal of Obesity, vol. 29, no. 10, pp. 1168-1174, 2005.
45. J. T. Devlin and E. S. Horton, "Effects of prior high-intensity exercise on glucose metabolism in normal and insulin-resistant men," Diabetes, vol. 34, no. 10, pp. 973-979, 1985.
46. S. A. Newsom, A. C. Everett, A. Hinko, and J. F. Horowitz, "A single session of low-intensity exercise is sufficient to enhance insulin sensitivity into the next day in obese adults," Diabetes Care, vol. 36, no. 9, pp. 2516-2522, 2013.
47. J. A. Romijn, E. F. Coyle, L. S. Sidossis et al., "Regulation of endogenous fat and carbohydrate metabolism in relation to exercise intensity and duration," The American Journal of Physiology - Endocrinology and Metabolism, vol. 265, no. 3, pp. E380-E391, 1993.
48. N. Gao, Z. Zhang, B.-H. Jiang, and X. Shi, "Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer," Biochemical and Biophysical Research Communications, vol. 310, no. 4, pp. 1124-1132, 2003.
49. K. E. O'Reilly, F. Rojo, Q.-B. She et al., "mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt," Cancer Research, vol. 66, no. 3, pp. 1500-1508, 2006.
50. Z.-P. Chen, T. J. Stephens, S. Murthy et al., "Effect of exercise intensity on skeletal muscle AMPK signaling in humans," Diabetes, vol. 52, no. 9, pp. 2205-2212, 2003.
51. D. Vavvas, A. Apazidis, A. K. Saha et al., "Contraction-induced changes in acetyl-CoA carboxylase and 5′-AMP- activated kinase in skeletal muscle," The Journal of Biological Chemistry, vol. 272, no. 20, pp. 13255-13261, 1997.
52. J. N. Nielsen, K. J. W. Mustard, D. A. Graham et al., "5′-AMP-activated protein kinase activity and subunit expression in exercise-trained human skeletal muscle," Journal of Applied Physiology, vol. 94, no. 2, pp. 631-641, 2003.
53. R. Bergeron, R. R. Russell III, L. H. Young et al., "Effect of AMPK activation on muscle glucose metabolism in conscious rats," The American Journal of Physiology - Endocrinology and Metabolism, vol. 276, no. 5, pp. E938-E944, 1999.
54. R. R. Russell III, R. Bergeron, G. I. Shulman, and L. H. Young, "Translocation of myocardial GLUT-4 and increased glucose uptake through activation of AMPK by AICAR," American Journal of Physiology - Heart and Circulatory Physiology, vol. 277, no. 2, pp. H643-H649, 1999.
55. L. W. Jones, B. L. Viglianti, J. A. Tashjian et al., "Effect of aerobic exercise on tumor physiology in an animal model of human breast cancer," Journal of Applied Physiology, vol. 108, no. 2, pp. 343-348, 2010.
56. K. A. Simpson and M. A. F. Singh, "Effects of exercise on adiponectin: a systematic review," Obesity, vol. 16, no. 2, pp. 241-256, 2008.
57. M. Zakikhani, R. J. O. Dowling, N. Sonenberg, and M. N. Pollak, "The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase," Cancer Prevention Research, vol. 1, no. 5, pp. 369-375, 2008.
58. C.-H. Tang and M.-E. Lu, "Adiponectin increases motility of human prostate cancer cells via AdipoR, p38, AMPK, and NF-κB pathways," Prostate, vol. 69, no. 16, pp. 1781-1789, 2009.
59. J. R. Rider, M. Fiorentino, R. Kelly et al., "Tumor expression of adiponectin receptor 2 and lethal prostate cancer," Carcinogenesis, vol. 36, no. 6, pp. 639-647, 2015.
60. B. Faubert, G. Boily, S. Izreig et al., "AMPK is a negative regulator of the warburg effect and suppresses tumor growth in vivo," Cell Metabolism, vol. 17, no. 1, pp. 113-124, 2013.
61. H. Harada, S. Itasaka, S. Kizaka-Kondoh et al., "The Akt/mTOR pathway assures the synthesis of HIF-1α protein in a glucose- and reoxygenation-dependent manner in irradiated tumors," The Journal of Biological Chemistry, vol. 284, no. 8, pp. 5332-5342, 2009.
62. Y. Storozhuk, S. N. Hopmans, T. Sanli et al., "Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK," British Journal of Cancer, vol. 108, no. 10, pp. 2021-2032, 2013.
63. K. Nowak, H. Eldredge-Hindy, and C. Champ, "Metformin: the sweet link between tumor genetics and metabolism?" OA Cancer, vol. 2, no. 1, p. 7, 2014, http://www.oapublishinglondon.com/article/1298.
64. V. E. Zannella, D. Cojocari, S. Hilgendorf et al., "AMPK regulates metabolism and survival in response to ionizing radiation," Radiotherapy and Oncology, vol. 99, no. 3, pp. 293-299, 2011.
65. T. Sanli, A. Rashid, C. Liu et al., "Ionizing radiation activates AMP-activated kinase (AMPK): a target for radiosensitization of human cancer cells," International Journal of Radiation Oncology Biology Physics, vol. 78, no. 1, pp. 221-229, 2010.
66. M. Ristow, M. F. Pfister, A. J. Yee et al., "Frataxin activates mitochondrial energy conversion and oxidative phosphorylation," Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 22, pp. 12239-12243, 2000.
67. T. J. Schulz, R. Thierbach, A. Voigt et al., "Induction of oxidative metabolism by mitochondrial frataxin inhibits cancer growth: Otto Warburg revisited," The Journal of Biological Chemistry, vol. 281, no. 2, pp. 977-981, 2006.
68. G. R. Steinberg and B. E. Kemp, "AMPK in health and disease," Physiological Reviews, vol. 89, no. 3, pp. 1025-1078, 2009.
69. B. K. Pedersen, "Muscles and their myokines," Journal of Experimental Biology, vol. 214, no. 2, pp. 337-346, 2011.
70. N. Mathur and B. K. Pedersen, "Exercise as a mean to control low-grade systemic inflammation," Mediators of Inflammation, vol. 2008, Article ID 109502, 6 pages, 2008.
71. C. Keller, A. Steensberg, H. Pilegaard et al., "Transcriptional activation of the IL-6 gene in human contracting skeletal muscle: influence of muscle glycogen content," The FASEB Journal, vol. 15, no. 14, pp. 2748-2750, 2001.
72. B. K. Pedersen, A. Steensberg, P. Keller et al., "Muscle-derived interleukin-6: lipolytic, anti-inflammatory and immune regulatory effects," Pflugers Archiv European Journal of Physiology, vol. 446, no. 1, pp. 9-16, 2003.
73. L. J. Wood, L. M. Nail, and K. A. Winters, "Does muscle-derived interleukin-6 mediate some of the beneficial effects of exercise on cancer treatment-related fatigue?" Oncology Nursing Forum, vol. 36, no. 5, pp. 519-524, 2009.
74. T. G. Heck, C. M. Schöler, and P. I. H. de Bittencourt, "HSP70 expression: does it a novel fatigue signalling factor from immune system to the brain?" Cell Biochemistry and Function, vol. 29, no. 3, pp. 215-226, 2011.
75. O. Neubauer, D. König, and K.-H. Wagner, "Recovery after an Ironman triathlon: sustained inflammatory responses and muscular stress," European Journal of Applied Physiology, vol. 104, no. 3, pp. 417-426, 2008.
76. M. Kelly, M.-S. Gauthier, A. K. Saha, and N. B. Ruderman, "Activation of AMP-activated protein kinase by interleukin-6 in rat skeletal muscle: association with changes in cAMP, energy state, and endogenous fuel mobilization," Diabetes, vol. 58, no. 9, pp. 1953-1960, 2009.
77. G. van Hall, A. Steensberg, M. Sacchetti et al., "Interleukin-6 stimulates lipolysis and fat oxidation in humans," The Journal of Clinical Endocrinology & Metabolism, vol. 88, no. 7, pp. 3005-3010, 2003.
78. P. Rasmussen, P. Brassard, H. Adser et al., "Evidence for a release of brain-derived neurotrophic factor from the brain during exercise," Experimental Physiology, vol. 94, no. 10, pp. 1062-1069, 2009.
79. R. Chen, F. X. Liang, J. Moriya et al., "Chronic fatigue syndrome and the central nervous system," Journal of International Medical Research, vol. 36, no. 5, pp. 867-874, 2008.
80. R. J. Segal, R. D. Reid, K. S. Courneya et al., "Resistance exercise in men receiving androgen deprivation therapy for prostate cancer," Journal of Clinical Oncology, vol. 21, no. 9, pp. 1653-1659, 2003.
81. L. Bourke, S. Gilbert, R. Hooper et al., "Lifestyle changes for improving disease-specific quality of life in sedentary men on long-term androgen-deprivation therapy for advanced prostate cancer: a randomised controlled trial," European Urology, vol. 65, no. 5, pp. 865-872, 2014.
82. D. A. Galvão, N. Spry, J. Denham et al., "A multicentre year-long randomised controlled trial of exercise training targeting physical functioning in men with prostate cancer previously treated with androgen suppression and radiation from TROG 03.04 radar," European Urology, vol. 65, no. 5, pp. 856-864, 2014.
83. P. Cormie, D. A. Galvão, N. Spry et al., "Can supervised exercise prevent treatment toxicity in patients with prostate cancer initiating androgen-deprivation therapy: a randomised controlled trial," BJU International, vol. 115, no. 2, pp. 256-266, 2015.
84. R. J. Segal, R. D. Reid, K. S. Courneya et al., "Randomized controlled trial of resistance or aerobic exercise in men receiving radiation therapy for prostate cancer," Journal of Clinical Oncology, vol. 27, no. 3, pp. 344-351, 2009.
85. U. Monga, S. L. Garber, J. Thornby et al., "Exercise prevents fatigue and improves quality of life in prostate cancer patients undergoing radiotherapy," Archives of Physical Medicine and Rehabilitation, vol. 88, no. 11, pp. 1416-1422, 2007.
86. P. L. Nguyen, M.-H. Chen, C. J. Beard et al., "Radiation with or without 6 months of androgen suppression therapy in intermediate- and high-risk clinically localized prostate cancer: a postrandomization analysis by risk group," International Journal of Radiation Oncology Biology Physics, vol. 77, no. 4, pp. 1046-1052, 2010.
87. N. L. Keating, A. J. O'Malley, and M. R. Smith, "Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer," Journal of Clinical Oncology, vol. 24, no. 27, pp. 4448-4456, 2006.
88. A. W. Hsing, Y.-T. Gao, S. Chua Jr., J. Deng, and F. Z. Stanczyk, "Insulin resistance and prostate cancer risk," Journal of the National Cancer Institute, vol. 95, no. 1, pp. 67-71, 2003.
89. S. Lehrer, E. J. Diamond, S. Stagger, N. N. Stone, and R. G. Stock, "Increased serum insulin associated with increased risk of prostate cancer recurrence," Prostate, vol. 50, no. 1, pp. 1-3, 2002.
90. J. R. Gardner, P. M. Livingston, and S. F. Fraser, "Effects of exercise on treatment-related adverse effects for patients with prostate cancer receiving androgen-deprivation therapy: a systematic review," Journal of Clinical Oncology, vol. 32, no. 4, pp. 335-346, 2014.
91. T. S. Nilsen, T. Raastad, E. Skovlund et al., "Effects of strength training on body composition, physical functioning, and quality of life in prostate cancer patients during androgen deprivation therapy," Acta Oncologica, vol. 54, no. 10, pp. 1805-1813, 2015.
92. J. M. Harrington, D. C. Schwenke, and D. R. Epstein, "Exercise preferences among men with prostate cancer receiving androgen-deprivation therapy," Oncology Nursing Forum, vol. 40, no. 5, pp. E358-E367, 2013.
93. M. R. Harrison and L. W. Jones, "Exercise as treatment for androgen deprivation therapy-associated physical dysfunction: ready for prime time?" European Urology, vol. 65, no. 5, pp. 873-874, 2014.
94. P. Ekkekakis, E. E. Hall, and S. J. Petruzzello, "Some like it vigorous: measuring individual differences in the preference for and tolerance of exercise intensity," Journal of Sport & Exercise Psychology, vol. 27, no. 3, pp. 350-374, 2005.
95. F. T. Baumann, E. M. Zopf, and W. Bloch, "Clinical exercise interventions in prostate cancer patients-a systematic review of randomized controlled trials," Supportive Care in Cancer, vol. 20, no. 2, pp. 221-233, 2012.
96. T. H. Lee, Ed., Calories Burned in 30 Minutes for People of Three Different Weights - Harvard Health, Harvard Health Publications, 2004, http://www.health.harvard.edu.